10 products found
Aphios Corporation Products
-
Oncology Therapeutic
Cancer is an insidious and tragic disease affecting millions of Americans, often when they are in their prime. Breast cancer will affect 1 of every 8 women in the United States, with around 230,000 new cases diagnosed and 40,000 deaths each year. Prostate cancer will affect 1 of every 6 men in the United States, with 240,000 new cases diagnosed and 34,000 deaths each year. There are several other difficult to diagnose and treat cancers such as pancreatic cancer that has recently claimed the lives of Apple genius Steve Jobs, the immunology Nobel Prize winner Dr. Ralph Steinman, the great actor-dancer Patrick Wayne Swayze and a number of unheralded Americans. Cancers not only cause untimely deaths but often significantly impact the quality of life, partly owing to cancer itself and partly because of nausea and vomiting caused by chemotherapy treatment.
-
Aphios - Model Zindol - Chemotherapy
Despite the widespread use of the 5-HT3 receptor antagonist anti-emetics such as Palonosetron (Aloxi; Eisai), Ondansetron (Zofran®; GSK), Granisetron (Kytril®; Roche Pharmaceuticals), and Dolasetron (Anzemet®; Aventis), CINV continues to be reported by up to 70% of adult patients receiving highly emetogenic chemotherapy agents and 58% of school-age and adolescent-age children receiving highly emetogenic chemotherapy. Anticipatory nausea (AN) ...
-
Aphios - Model APH-0701 - Prostate Cancer Prevalence and Demographics
Prostate cancer is the most prevalent cancer among men, and it is the second leading cause of cancer death among men in the United States. More than 500,000 cases are diagnosed annually. In the U.S. this year, 1 in 6 males will develop the disease and 30,000 others will die of it. Although prostate cancer mostly affects elderly men, the number of younger men with prostatic carcinoma is significant. In addition, the general increase in longevity has ...
-
Aphios - Model APH-0911 - Taxoid Sugar Pills (Prodrugs)
Poor Solubility and Associated Formulation and Bioavailability Difficulties. Although paclitaxel is an effective anticancer drug, its solubility is low (~ 0.4 µg/mL), which limits its medical utility to intravenous applications. Docetaxel (Taxotere®) was developed as a paclitaxel derivative having improved water solubility; its solubility, however, is only ~ 14 µg/mL. Several encapsulation techniques have been utilized to reformulate ...
-
Aphios - Model APH-0912 - Combination of A Taxotere® Prodrug And Monoclonal Antibody
APH-0912 is a combination of a Taxotere® prodrug and monoclonal antibody targeted to treat metastatic cancer. The prodrug is a combination of a docetaxel molecule, the potent anticancer drug, and a sugar molecule to enhance solubility covalently linked to a tumor-specific antibody. This molecular combination is not bioactive prior to administration. After infusion and adsorption onto targeted cancer cells facilitated by the cancer-specific monoclonal ...
-
Infectious Disease Therapeutic
Infectious diseases are a scourge to humanity dating back to our prehistoric ancestors. In the last millennium (peaking between AD 1348 and AD 1350), the black plague – caused by the bacterium Yersiva pestis and exacerbated by poor sanitary conditions – devastated Europe, killing 30-60% of the population. Smallpox traced back to 1,000 BC in Egyptian mummies, was introduced to the Americas by Spanish conquistadors in the 15th century, where it decimated 80-90% of the Amerindian populations. Smallpox is thought to be responsible for 300-500 million deaths in the 20th century.
-
Aphios - Model APP-0205, APP-309 - Anti-Influenza Therapeutics
Flu – A Serious, Deadly Disease with Pandemic Potential. In 1918, the Spanish flu (H1N1 influenza virus) rapidly killed 50 to 100 million people worldwide, affecting one of every five Americans. Today, influenza remains a common and serious respiratory illness that contributes to the reduction of quality of life and results in a significant loss of manpower hours each year. Every year, 40 million Americans catch the flu and 20,000 to 40,000 ...
-
Aphios - Vaccine Adjuvant Technology
Vaccination is the most cost-effective tool for the control and prevention of infectious diseases. However, multiple inoculations are often required to achieve desirable protection even with potent antigens. In order to increase the therapeutic efficiency of such vaccines, adjuvants are used with vaccines to augment the immune response. There are several types of adjuvants with different modes of action. Adjuvants form a depot of antigen at the site of ...
-
Aphios - Model APH-0812 - Combination Therapy
A combination therapy consisting of PKC agonists with or without HDAC inhibitors, designed to reactivate latent HIV reservoirs so that HIV can be eliminated by antiviral therapy and eradicated from the body. HIV Latency: Although highly active antiretroviral therapy (HAART) is undoubtedly a lifesaving therapy for millions of AIDS patients, the persistence of latent HIV-infected cellular reservoirs represents a major hurdle to virus eradication. Latently ...
-
Model APH-0202 - Oral Nanoformulation Containing Betulinic Acid
An orally bioavailable nanoformulation of betulinic acid that works as an HIV maturation inhibitor. APH-0202 is an oral nanoformulation containing betulinic acid. A pentacyclic triterpene, betulinic acid is a component of the bark of the white birch tree, Betula alba. Phospholipid nanosomes can be utilized to enhance the formulation and efficacy of betulinic acid. Oral bioavailability can be enhanced by nanoencapsulating betulinic acid nanosomes and/or ...
-
CNS Disorders
Experts estimate that 22 million people around the world and more than 8 million Americans will be afflicted with Alzheimer’s Disease (AD) by 2025. Due to the changing demographics, the number of people with AD is expected to grow quickly. The number of AD patients is expected to grow at an annual rate of 17.5%. Leading AD drugs are reversible cholinesterase inhibitors: Aricept®, Razadyne®, Exelon®, and Cognex®. This approach has proven to be inadequate, providing more of a band-aid than substantive relief for AD patients, with significant side effects of nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia. These drug regimens may benefit from our anti-nausea drug, Zindol®, under development, and its dietary supplement counterpart, Zindol® DS.
-
Model APH-1104 - Novel a-Secretase Modulator and Potential AD Therapeutic
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by α-secretase activation via novel PKC isoforms, down-regulation of pro-inflammatory and angiogenic processes and the substitution of β-amyloid for its soluble and harmless relative, s-APPα. Aphios has ...
-
Model Xantol - Enhanced St. John’s Wort Botanical Drug
An enhanced St. John’s Wort botanical product standardized by hyperforin for use as an alternative to prescription antidepressants. Xantol™ is an enhanced St. John’s Wort (SJW) product standardized by hyperforin content [US Patent]. Aphios utilized its patented SuperFluids™ fractionation ...